Marina Temkin

Pension system re-ups with Flagship Pioneering and IDG China Venture Capital.

LPs also discuss liquidity concerns and the denominator effect amid the pandemic and the economic slowdown.

Silicon Valley VC deal price increases slowed over the course of Q1 2020, according to Fenwick & West’s survey. Start-ups are looking to various deal structures to extend their cash runway.

Kindler, whose role with the firm will center around advising on investments, expects tech to increase healthcare's innovation cycle. ARTIS invests at the intersection of biopharma and technology.

VC dealmaking remained robust during the first three months of the year, but this trend is likely already reversing, according to the latest report from PitchBook and NVCA.

TCRS invested $150 million toward General Catalyst's latest funds, which totaled $2.3 billion. The pension system held its March board meeting via Zoom.

Amid the covid-19 outbreak, four biotech funds closed on $3.8 billion in over a week and a half.

Many VC investors came into 2020 underallocated into the asset class. They want to wait until the market stabilizes to assess if portfolios need to be rebalanced.

It has become an important source of capital for start-ups in recent years. But corporate investing will likely pull back substantially during the downturn.

Telemedicine valuations will rise following substantial adoption growth, and investors see a compelling thesis around these services even after coronavirus fears abate.